The LATITUDE (Long-Acting Therapy to Improve Treatment Success in Daily Life trial (ACTG A5359) study received extensive media attention on its recent opening. LATITUDE is evaluating long-acting ART (monthly injections of injections of rilpivirine and cabotegravir) in individuals who have difficulty adhering to daily oral ART. The study, which opened in May at several U.S. sites, garnered significant media attention in outlets including POZ, Bloomberg, Pharmafile, and many others. Read the study news release here. Congratulations to the LATITUDE team on the successful launch of this important new trial!
LATITUDE Study (A5359) Garners Widespread Media Attention
Jun 30, 2019